BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up to $1.75

Posted by Logan Wallace on Nov 18th, 2019

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) gapped up prior to trading on Monday . The stock had previously closed at $1.80, but opened at $1.75. BioCryst Pharmaceuticals shares last traded at $1.82, with a volume of 194,248 shares trading hands.

A number of equities analysts have issued reports on the stock. HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Thursday, October 31st. ValuEngine lowered shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, November 4th. Needham & Company LLC reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Wednesday, November 6th. BidaskClub lowered shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, October 4th. Finally, Zacks Investment Research lowered shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $8.94.

The company has a quick ratio of 1.43, a current ratio of 0.96 and a debt-to-equity ratio of 2.38. The firm has a market capitalization of $175.04 million, a PE ratio of -1.77 and a beta of 1.86. The firm’s fifty day simple moving average is $2.38 and its 200-day simple moving average is $3.53.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.03). BioCryst Pharmaceuticals had a negative net margin of 1,129.38% and a negative return on equity of 2,511.40%. The company had revenue of $1.78 million for the quarter, compared to analysts’ expectations of $4.54 million. As a group, analysts predict that BioCryst Pharmaceuticals, Inc. will post -1.25 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the business. UBS Asset Management Americas Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 7.9% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 65,958 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 4,803 shares during the period. Bank of Montreal Can grew its position in BioCryst Pharmaceuticals by 921.9% in the second quarter. Bank of Montreal Can now owns 10,219 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 9,219 shares in the last quarter. Commonwealth Equity Services LLC grew its position in BioCryst Pharmaceuticals by 22.8% in the second quarter. Commonwealth Equity Services LLC now owns 53,230 shares of the biotechnology company’s stock valued at $201,000 after acquiring an additional 9,900 shares in the last quarter. Quantamental Technologies LLC acquired a new stake in BioCryst Pharmaceuticals in the second quarter valued at approximately $43,000. Finally, Rhumbline Advisers grew its position in BioCryst Pharmaceuticals by 8.4% in the third quarter. Rhumbline Advisers now owns 175,062 shares of the biotechnology company’s stock valued at $502,000 after acquiring an additional 13,631 shares in the last quarter. 92.40% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.